| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_2e72837de81999e7e72cb78d59d19e28 |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2333-918
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2800-32 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-573
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-92
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q1-44 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61B5-0205
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K16-40
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N33-573
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12Q1-44 |
| filingDate |
2009-03-16-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_745c3041b9d8cc1f0a96da0af69c2f0e
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_5a3d4c26c4d6d39f0da02a5e75cf4c01
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_1ff96c6a034136401929edd2cc2072c8 |
| publicationDate |
2011-08-18-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
US-2011201947-A1 |
| titleOfInvention |
Oxidized paraoxonase 1 and paraoxonase 1/hdl particle number ratio as risk markers for cardiovascular disease |
| abstract |
The present invention provides methods and markers for characterizing a subject's, particularly a human subject risk of having cardiovascular disease. The present invention also provides methods of characterizing a subject's risk of developing cardiovascular disease. In another embodiment, the present invention provides methods for characterizing a subject's risk of experiencing a complication of cardiovascular disease or major adverse cardiac event within 1, 3, or 10 years. In another embodiment, the present invention provides a method for determining whether a subject presenting with chest pain is at risk near term of experiencing a heart attack or other major adverse cardiac event. The present methods are especially useful for identifying those subjects who are in need of highly aggressive CVD therapies as well as those subjects who require no therapies targeted at inhibiting or preventing CVD or complications of CVD. |
| isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-9483611-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-9483612-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-11703501-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2022197819-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-10386355-B2 |
| priorityDate |
2008-03-14-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |